Study group | Control group | p-value | ||
---|---|---|---|---|
Subjects | 155 | 161 | ||
Age (years), mean (SD) | 51.74 (12.05) | 50.74 (13.12) | 0.4801 | |
Gender, n (%) | Female | 99 (63.9) | 102 (63.4) | 0.9239 |
Male | 56 (36.1) | 59 (36.6) | ||
Ethnicity (%) | Caucasian | 145 (93.5) | 147 (91.3) | 0.6215 |
Latin American | 7 (4.5) | 10 (6.2) | ||
Other | 3 (2.0) | 4 (2.5) | ||
Time since diagnosis (months), mean (SD) | 58.89 (93.29) | 61.52 (95.80) | 0.8050 | |
Main diagnosis, n (%) | Major depression | 146 (94.2) | 148 (91.9) | 0.7035 |
Dysthymic disorder | 5 (3.2) | 8 (5.0) | ||
Other non-specified depressive disorder | 4 (2.6) | 5 (3.1) | ||
Clinical Global Impression-Severity (CGI-S) scale, clinician-rated, mean (SD) | 4.50 (0.62) | 4.40 (0.57) | 0.1663 | |
Hamilton Depression Rating Scale (HDRS-17), mean (SD) | 19.47 (5.96) | 19.01 (5.71) | 0.4818 | |
Patient Global Impression of Improvement scale (PGI-I), single-blinded inclusion criterion, n (%) | No change | 108 (69.7) | 123 (76.4) | 0.4026 |
A little worse | 26 (16.8) | 20 (12.4) | ||
Much worse | 16 (10.3) | 16 (9.9) | ||
Very much worse | 5 (3.2) | 2 (1.2) | ||
Previous failed psychiatric medication trials, mean (SD) | 2.55 (2.35) | 2.57 (2.10) | 0.9175 |